SCHEMBL20200085

SCHEMBL20200085

O=C(Cc1ccc(-c2cn3ccccc3n2)cc1)c1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 12/20 0.58
NPC1 O15118 11/20 0.58
KDM4E B2RXH2 11/20 0.58
SMN1; SMN2 Q16637 7/20 0.58
ALDH1A1 P00352 7/20 0.58
HPGD P15428 5/20 0.58
ADRB2 P07550 1/20 0.58
PTGS1 P23219 1/20 0.57
PTGS2 P35354 1/20 0.57
GFER P55789 4/20 0.57
POLB P06746 2/20 0.55
LMNA P02545 2/20 0.53
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
NPSR1 Q6W5P4 2/20 0.53
HDAC6 Q9UBN7 1/20 0.52
CYP2C19 P33261 1/20 0.52
HTT P42858 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
PKM P14618 4/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20200097 0.95 PTGS1 (0.57) RAB9ANPC1KDM4ESMN1; SMN2ALDH1A1
SCHEMBL11824079 0.88 RAB9A (0.61) RAB9ANPC1KDM4ESMN1; SMN2ALDH1A1
SCHEMBL11824996 0.84 RAB9A (0.60) RAB9ANPC1KDM4ESMN1; SMN2ALDH1A1
SCHEMBL3440320 0.81 RAB9A (0.66) RAB9ANPC1KDM4ESMN1; SMN2ALDH1A1
SCHEMBL13325928 0.79 RAB9A (0.68) RAB9ANPC1KDM4ESMN1; SMN2ALDH1A1
SCHEMBL11825664 0.79 RAB9A (0.61) RAB9ANPC1KDM4ESMN1; SMN2ALDH1A1
SCHEMBL11824355 0.79 RAB9A (0.59) RAB9ANPC1KDM4ESMN1; SMN2ALDH1A1
SCHEMBL12916066 0.79 PTGS1 (0.59) RAB9ANPC1KDM4ESMN1; SMN2ALDH1A1
SCHEMBL13325909 0.78 RAB9A (0.83) RAB9ANPC1KDM4ESMN1; SMN2ALDH1A1
SCHEMBL13325735 0.77 RAB9A (0.75) RAB9ANPC1KDM4ESMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180148410-A1 COMPOUNDS AND METHODS FOR TREATING CANCER DANA-FARBER CANCER INSTITUTE, INC. 2018-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180148410-A1 COMPOUNDS AND METHODS FOR TREATING CANCER GLI1, SHH, HRAS RAB9A 1517/4885NPC1 350/4885KDM4E 914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.